Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows 2.6% year over year
Q1 FY2026 operating expenses of $456.54K rose 2.6% year over year. Sequentially, it rose 78.7% from the prior quarter.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 1.2M USD
- Year-over-year change
- +169835.6%
- 1-year CAGR
- +169835.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.2M | +169835.6% |
| FY2024 | 2024-12-31 | 704 | — |
Operating Expenses vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's LTM Mar 2026 operating expenses of $1.21M is the 8th highest of the 10 companies compared; the peer median is $1.95M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | LTM Mar 2026 | $6.53M | +972.0% | — | — |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | LTM Mar 2026 | $3.62M | — | — | — |
| LTM Mar 2026 | $2.38M | -72.8% | -20.4% | — | |
| LTM Mar 2026 | $2.18M | — | — | — | |
| LTM Mar 2026 | $1.95M | — | — | — | |
| LTM Mar 2026 | $1.44M | — | — | — | |
| LTM Mar 2026 | $1.37M | +251.8% | -9.5% | — | |
OACCOaktree Acquisition Corp. III Life Sciences | LTM Mar 2026 | $1.21M | — | — | — |
| LTM Mar 2026 | $846.65K | — | — | — | |
COPLCopley Acquisition Corp | LTM Mar 2026 | $85.88K | — | — | — |
| Peer median (excluding OACC) | $1.95M | +251.8% | -14.9% | — | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 704 | 1.2M |
| Operating Expenses | 704 | 1.2M |
| Depreciation & Amortization | 704 | 0 |
| EBITDA | (351.81K) | (1.2M) |
| EBITDA Margin | — | — |
| Operating Income | (703) | (1.2M) |
| Operating Margin | — | — |
| Interest Income | 1.59M | 8.48M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 3.37K | 8.48M |
| Income Before Tax | 2.66K | 7.29M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | 2.66K | 7.29M |
| Net Margin | — | — |
| EPS (Basic) | 0.05 | 0.30 |
| EPS (Diluted) | 0.05 | 0.30 |
| Weighted Avg Shares | 24.58M | 19.2M |
| Weighted Avg Shares (Diluted) | 24.58M | 19.2M |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.